Wockhardt is a global pharmaceutical and biotechnology organization engaged in manufacturing finished dosage formulations, injectables, biopharmaceuticals, orals and topicals (creams and ointments). The company is amongst the top 3 Indian generic companies in the UK and the 6th largest generic supplier in the retail and hospital channels in Ireland. It is the No. 1 Methycobalamin brand in India. The company focuses its Biosimilar program on the anti-diabetic space. This vertical grew by 46% YoY in H1 FY25, driven by increasing volumes across key markets like Thailand, Algeria, Latin America, and India. It plans to launch insulin analogs in the next few quarters and expand its presence across new markets including Russia, Malaysia, Brazil, and Saudi Arabia. Presenting below are its Q1 FY26 earnings results.
Q1 FY26 Earnings Results
-
Total Revenue: ₹738 crore, down 0.14% year-over-year (YoY) from ₹747 crore in Q1 FY25; steady quarter-on-quarter (QoQ) trend.
-
EBITDA: ₹101 crore, EBITDA margin 13.7% (vs 13.4% YoY); EBITDA before R&D ₹128 crore, margin 17.4%.
-
Net Loss (PAT): –₹108 crore, widened significantly vs –₹16 crore in Q1 FY25 and improved vs –₹177 crore in Q4 FY25.
-
Profit Before Tax (PBT): –₹109 crore; includes an exceptional item charge of ₹97 crore.
-
EPS: –₹5.54 (down from –₹0.90 YoY, but improved from –₹11.60 QoQ).
-
Total Expenses: ₹770 crore, down 0.6% YoY; decline mainly benefited from reduced cost structures, though top-line pressure persisted.
-
R&D Spend: ₹27 crore (3.7% of sales).
Management Commentary & Strategic Highlights
-
Margins remained stable despite persistent losses, thanks to ongoing cost discipline.
-
Loss surge resulted primarily from exceptional item charges and elevated tax expenses last year.
-
Wockhardt continues to pivot toward pre-launch and launch activities for its pipeline in India/developed markets—specifically novel antibiotics and diabetes biosimilars.
-
“ZAYNICH®” (Zidebactam/Cefepime) filed for approval in India; pre-NDA meetings with US FDA completed.
-
Ongoing development and launches focus on high-value specialty drugs targeting key infection indications.
-
International business continued to contribute strongly (76% of revenue), with operations in Europe, India, and manufacturing in Ireland.
-
Company aims to improve profitability through operational excellence and strategic portfolio investments.
Q4 FY25 Earnings Results
-
Revenue: ₹743 crore, up by 6 percent on the YoY basis.
-
Net Loss (PAT): –₹45 crore vs -₹177 crore during the same quarter last year
-
EBITDA: ₹79 crore; margin 10.7%.
-
Losses were higher in Q4 due to exceptional charges and one-off adjustments.
To view the company’s previous earnings and latest concall transcripts, click here to visit the Alphastreet India news channel.